Nexalin Technology (NASDAQ:NXL – Get Free Report) and RenovoRx (NASDAQ:RNXT – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.
Profitability
This table compares Nexalin Technology and RenovoRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
| RenovoRx | -469.02% | -133.49% | -101.50% |
Risk and Volatility
Nexalin Technology has a beta of 4.31, suggesting that its stock price is 331% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Institutional & Insider Ownership
0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by insiders. Comparatively, 9.4% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Nexalin Technology and RenovoRx”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexalin Technology | $300,000.00 | 3.58 | -$8.22 million | ($14.41) | -0.10 |
| RenovoRx | $1.12 million | 50.83 | -$11.17 million | ($0.31) | -3.81 |
Nexalin Technology has higher earnings, but lower revenue than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for Nexalin Technology and RenovoRx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
| RenovoRx | 1 | 0 | 2 | 1 | 2.75 |
RenovoRx has a consensus price target of $8.50, indicating a potential upside of 620.34%. Given RenovoRx’s stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than Nexalin Technology.
Summary
RenovoRx beats Nexalin Technology on 11 of the 14 factors compared between the two stocks.
About Nexalin Technology
Nexalin Technology, Inc. (NASDAQ:NXL) is a medical technology company focused on developing and commercializing noninvasive neurostimulation devices for mental health and neurological applications. Its technology is designed to deliver low-intensity electrical stimulation to the brain with the goal of influencing neural activity associated with conditions such as depression, anxiety, insomnia, post-traumatic stress disorder and substance-use disorders. The company’s product portfolio includes the Gen-2 and Gen-3 neurostimulation systems.
About RenovoRx
RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue. RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
